Novo Nordisk
COPENHAGEN, Denmark, June 6, 2011 -
Nearly one in five people with diabetes are regularly unable to attend a
full day at work due to disruption caused by episodes of dangerously low
blood sugar, known as a hypoglycaemic event.
ZURICH, July 19, 2010 - Today, Novo Nordisk announced the landmark recruitment of the 60,000th
patient in the A1chieve(R) study - an observational study designed to
investigate the effects of modern insulins in the management of type 2
diabetes.[1]
Spanning 28 countries across 4 continents and involving more than 3300
physicians, A1chieve(R) is set to be the world's largest observational study
in insulin therapy.
COPENHAGEN - Novo Nordisk has been awarded a Good Design Award(TM)(1) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R).
LONDON - A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years - an incidence rate exceeding all previous predictions.(1) Studies in the USA and other countries also suggest similar trends.(2)
In the latest issue of Diabetic Hypoglycemia (www.hypodiab.com), Dr Tim Jones and Dr Trang Ly of the University of Western Australia maintain that, despite modern therapy, hypoglycemia remains a critical concern in these young patients.
